Pre-made Batoclimab benchmark antibody ( Whole mAb, anti-FCGRT therapeutic antibody, Anti-FCRN/FcgammaRn/alpha-chain Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Batoclimab biosimilar, Whole mAb, Anti-FCGRT Antibody: Anti-FCRN/FcgammaRn/alpha-chain therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Batoclimab (HBM9161) is a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn) that accelerates the degradation of autoantibodies that drive NMOSD as well as other autoimmune disorders. … NMOSD is a serious autoimmune disease of the central nervous system with no approved effective treatment.
| Products Name (INN Index) | Pre-Made Batoclimab biosimilar, Whole mAb, Anti-FCGRT Antibody: Anti-FCRN/FcgammaRn/alpha-chain therapeutic antibody |
|---|---|
| INN Name | Batoclimab |
| Target | FCGRT |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Immunovant Sciences |
| Conditions Approved | NA |
| Conditions Active | Graves¡¯ Ophtalmopathy,Myasthenia gravis,Autoimmune disorders,Neuromyelitis optica,Idiopathic thrombocytopenic purpura |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | FCGRT |
| Package |
